Tag Archives: drug

Rethinking drugs’ development in acute heart failure?

The ten drugs developed in AHF during the last two decades

Acute heart failure (AHF) affects 1-2% of adults in developed countries. It strikes mainly people above the age 60, peeking in those older than 85 (prevalence ~ 17.4%). AHF is a life threatening medical event, with gradual

International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems. Osaka, Japan. September 09-10, 2019

Cientific Group is overpowered to declare its absolute first “International Conference and Exhibition on Pharmaceutics and Novel Drug Delivery Systems”. Pharma Conferences hung on September 09-10, 2019 at Osaka, Japan. Pharmaceutica – 2019 gives a general stage

Cellular stress and AMPK activators including metformin and the anesthetic drug propofol promote restoration of human consciousness

Cellular stress and AMPK activators including Metformin

The neural mechanisms that give rise to human consciousness have been described as one of the greatest and most profound mysteries in all of modern medicine. The use of general anesthetics to induce loss of consciousness (LOC)

Bacteriocin AS-48: a potent drug against sleeping sickness

Graphical abstract about AS-48 activity against Trypanosoma brucei.

African trypanosomiasis has been a historical scourge on the African continent and one of the major causes of poverty. It is responsible for sleeping sickness in humans (HAT), and it avoids the development of agriculture based on

International Conference on Pharmaceutical Sciences and Drug delivery. Milan, Italy. November 18-19, 2019

International Conference on Pharmaceutical Sciences and Drug delivery

Theme: Optimizing Research reforms of the Pharmaceutical Industry. We cordially invite each and every interested and enthusiastic participant from all over the world to take part in the International Conference on Pharmaceutical Sciences and Drug delivery, at

Advances in drug discovery and development in geriatric psychiatry

Drug discovery for disorders of the central nervous system is a long and challenging process, with a high attrition rate from the preclinical stages through to marketing a compound. In geriatric psychiatry, the heterogeneous nature of these

Lernaean hydra puzzle in compensatory angiogenesis and tumor drug resistance

Diagrammatic representation of how compensatory angiogenic mechanisms are driven by redendent proangiogenic signalling

Before we proceed to apply the analogy of Lernaean hydra to compensatory angiogenesis and tumor drug resistance against anti-angiogenic drugs (AADs), let us have a cursory look at the interesting mythology of this hydra. According to Greek

A drug resistance gene mediates stringent response in bacteria

Model for physiological roles of M. smegmatis Arr

Mycobacteria represent an important group of bacteria. Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), infects about a third of the world population, of which 5% to 15% develop active disease. Furthermore, a rapid emergence of multidrug

Statins: Good for the heart, but do they impact the brain?

High cholesterol, termed hyperlipidemia, is a risk factor for cardiovascular disease. Therefore, keeping cholesterol levels low through diet and exercise has proven benefits for reducing heart disease risk. For adults who cannot meet their cholesterol targets through

Compounded medication for patients with rare diseases

Pharmaceutical compounding is the preparation of unlicensed medicines in order to meet specific patient needs that do not have a licensed (commercial) medicine available on the market. Especially for patients with rare diseases it is complementary when

A new strategy to drug development for neuromuscular disorder

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a neurodegenerative disease in which motor neuron (MN) loss in both the spinal cord and motor cortex causes progressive paralysis, muscle atrophy, and death. So far,

Estimating effects of new psychoactive substances (NPS) based on in vitro neurotoxicity data

The use of new psychoactive substances (NPS) is increasing and currently > 600 NPS have been reported. However, limited information on neuropharmacological and toxicological effects of NPS is available, hampering risk characterization. We reviewed the literature on

A new strategy to deliver anti-cancer nanodrugs and decrease their toxic side effects by temporarily blunting the RES uptake using Intralipid®

Nanodrugs, or nanotechnology-based therapeutics, show great promise for treating a number of diseases, including cancer. However, an analysis of the literature from the past 10 years finds that in studies of cancer nanodrugs, a very small fraction

Diving into the mucus – PEG micelles for oral delivery

Swallowing a pill of paracetamol for headache is fast and easy. The drug can be administrated at a desired time and location without any pain or assistance. Such is not the case for biological drugs like insulin,

Profiling biologics in circulating human whole blood

Functional and safety assessments of biologics prior to first-in-human (FIH) is key to understand the mode-of-action and safety profile. We have made use of an ex-vivo whole blood assay for its potential in assessment of antibody-based drug

A new drug to improve drug-eluting stents in coronary artery disease

Patients with symptomatic coronary artery disease often receive stent treatment in obstructed coronary arteries of the heart. Even though current generation drug-eluting stents perform very well in the short-term, concerns still exist about their long-term efficacy due

Cellular assay: bottleneck of the drug discovery process

Finding a needle in the haystack is not that difficult after all: Just use a strong magnet, and you have a good chance to get it. Picking up, among millions of different compounds, the right ones that

Electrifying drug delivery

Most patients with chronic illnesses are treated with oral drugs and injections. These delivery methods are plagued by low drug efficacy and nonspecific side effects. In addition, studies estimate that as high as 60% of the patients

Proline analogues present anti-Trypanosoma cruzi activity through inhibition of proline transporter

Trypanosoma cruzi is the protozoan parasite that causes Chagas disease, an illness that affects approximately 7 million people in Latin America. Nowadays there are only two drugs approved for Chagas treatment, benznidazole and nifurtimox. Both drugs were

Dilemma of a beneficial narcotic analgesic: Tramadol

Tramadol is a known opioid drug that is used worldwide to relieve moderate to severe pain. It is the sole over-the-counter narcotic drug, meaning that it can be purchased without a physician prescription. Most people can enjoy